{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:54:59Z","timestamp":1783137299317,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,1,16]],"date-time":"2006-01-16T00:00:00Z","timestamp":1137369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1245\/aso.2006.03.032","type":"journal-article","created":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T23:59:44Z","timestamp":1136937584000},"page":"205-213","source":"Crossref","is-referenced-by-count":14,"title":["HER-2\/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis"],"prefix":"10.1245","volume":"13","author":[{"given":"S. David","family":"Nathanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"DeBruyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Kapke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,16]]},"reference":[{"key":"9419_CR1","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.1996.03540220042028","volume":"276","author":"JJ Albertini","year":"1996","unstructured":"Albertini JJ, Lyman GH, Cantor A, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818\u20131822","journal-title":"JAMA"},{"key":"9419_CR2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1072-7515(00)00732-8","volume":"191","author":"JA Olson Jr","year":"2000","unstructured":"Olson JA Jr, Fey J, Winawer J, et al. Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg 2000;191:593\u20139","journal-title":"J Am Coll Surg"},{"key":"9419_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.0007-1323.2001.01962.x","volume":"89","author":"M Noguchi","year":"2002","unstructured":"Noguchi M. Sentinel lymph node biopsy and breast cancer. Br J Surg 2002;89:21\u201334","journal-title":"Br J Surg"},{"key":"9419_CR4","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/jnci\/djg076","volume":"95","author":"SB Edge","year":"2003","unstructured":"Edge SB, Niland JC, Bookman MA, et al. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 2003;95:1514\u201321","journal-title":"J Natl Cancer Inst"},{"key":"9419_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10434-004-1168-y","volume":"12","author":"MA Maggard","year":"2005","unstructured":"Maggard MA, Lane KE, O\u2019Connell JB, et al. Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer? Ann Surg Oncol 2005;12:41\u20137","journal-title":"Ann Surg Oncol"},{"key":"9419_CR6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546\u201353","journal-title":"N Engl J Med"},{"key":"9419_CR7","first-page":"489","volume-title":"Diseases of the Breast","author":"GM Clark","year":"2000","unstructured":"Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 489\u2013514","edition":"2"},{"key":"9419_CR8","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/cncr.10539","volume":"94","author":"GF Schwartz","year":"2002","unstructured":"Schwartz GF, Giuliano AE, Veronesi U. The consensus conference committee: proceedings of the consensus conference of the role of sentinel lymph node biopsy in carcinoma of the breast. April 19\u201322, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542\u201351","journal-title":"Cancer"},{"key":"9419_CR9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0002-9610(02)00939-X","volume":"184","author":"BJ Grube","year":"2002","unstructured":"Grube BJ, Hansen NM, Ye X, Giuliano AE. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. Am J Surg 2002;184:372\u20136","journal-title":"Am J Surg"},{"key":"9419_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1072-7515(00)00310-0","volume":"191","author":"MD Rivadeneira","year":"2000","unstructured":"Rivadeneira MD, Rache M, Simmons MD, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000;191:1\u20136","journal-title":"J Am Coll Surg"},{"key":"9419_CR11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<948::AID-CNCR21>3.0.CO;2-U","volume":"83","author":"I Olivotto","year":"1998","unstructured":"Olivotto I, Jackson J, Matas D, et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 1998;83:948\u201355","journal-title":"Cancer"},{"key":"9419_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1096-9098(199705)65:1<34::AID-JSO7>3.0.CO;2-P","volume":"65","author":"D Fein","year":"1997","unstructured":"Fein D, Fowble B, Hanlon A, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997;65:34\u20139","journal-title":"J Surg Oncol"},{"key":"9419_CR13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archsurg.137.5.606","volume":"137","author":"M Chen","year":"2002","unstructured":"Chen M, Palleschi S, Khoynezhad A, et al. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg 2002;137:606\u20139","journal-title":"Arch Surg"},{"key":"9419_CR14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1245\/ASO.2005.11.916","volume":"12","author":"B Cady","year":"2005","unstructured":"Cady B. Simplification of breast cancer surgery. Ann Surg Oncol 2005;12:6\u20138","journal-title":"Ann Surg Oncol"},{"key":"9419_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10434-004-1169-x","volume":"12","author":"JE Mendez","year":"2005","unstructured":"Mendez JE, Fey JV, Cody H, et al. Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology? Ann Surg Oncol 2005;12:24\u20138","journal-title":"Ann Surg Oncol"},{"key":"9419_CR16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ van de Vijver","year":"2002","unstructured":"van de Vijver MJ, He YD, van\u2019t Veer IJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999\u20132009","journal-title":"N Engl J Med"},{"key":"9419_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 1987;235:177\u201380","journal-title":"Science"},{"key":"9419_CR18","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","volume":"16","author":"MD Pegram","year":"1998","unstructured":"Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using a recombinant humanized anti-p185HER-2\/neu monoclonal antibody plus cisplatinum in patients with HER-2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659\u201369","journal-title":"J Clin Oncol"},{"key":"9419_CR19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/stem.160413","volume":"16","author":"JS Ross","year":"1998","unstructured":"Ross JS, Fletcher JA. The HER-2\/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413\u201328","journal-title":"Stem Cells"},{"key":"9419_CR20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/cncr.11464","volume":"98","author":"SD Nathanson","year":"2003","unstructured":"Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413\u201323","journal-title":"Cancer"},{"key":"9419_CR21","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1002\/cncr.10553","volume":"94","author":"W Yang","year":"2002","unstructured":"Yang W, Klos K, Yang Y, et al. ErbB2 over expression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002;94:2855\u201361","journal-title":"Cancer"},{"key":"9419_CR22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10434-001-0837-3","volume":"8","author":"SD Nathanson","year":"2001","unstructured":"Nathanson SD, Wachna DL, Gilman D, et al. Pathways of lymphatic drainage from the breast. Ann Surg Oncol 2001;8:837\u201343","journal-title":"Ann Surg Oncol"},{"key":"9419_CR23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"K-Y Liang","year":"1986","unstructured":"Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13\u201322.","journal-title":"Biometrika"},{"key":"9419_CR24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","volume":"42","author":"SL Zeger","year":"1986","unstructured":"Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121\u201330","journal-title":"Biometrics"},{"key":"9419_CR25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1524-4741.2003.09304.x","volume":"9","author":"SH Choi","year":"2003","unstructured":"Choi SH, Barsky SH, Chang HR. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer. Breast J 2003;9:153\u201362","journal-title":"Breast J"},{"key":"9419_CR26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1990.8.1.103","volume":"8","author":"S Paik","year":"1990","unstructured":"Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein over expression in primary breast cancer. J Clin Oncol 1990;8:103\u201310","journal-title":"J Clin Oncol"},{"key":"9419_CR27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1126\/science.2992090","volume":"229","author":"AL Schechter","year":"1985","unstructured":"Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976\u20138","journal-title":"Science"},{"key":"9419_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/stem.150001","volume":"15","author":"DM Reese","year":"1997","unstructured":"Reese DM, Slamon DJ. HER-2\/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997;15:1\u20138","journal-title":"Stem Cells"},{"key":"9419_CR29","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/bjc.1997.283","volume":"75","author":"C Charpin","year":"1997","unstructured":"Charpin C, Garcia S, Bouvier C, et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients\u2019 overall and disease-free survival. Br J Cancer 1997;75:1667\u201373","journal-title":"Br J Cancer"},{"key":"9419_CR30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/bjc.1991.101","volume":"63","author":"C Lovekin","year":"1991","unstructured":"Lovekin C, Ellis IO, Locker A, et al. C-erb-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439\u201343","journal-title":"Br J Cancer"},{"key":"9419_CR31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.2005.09.055","volume":"6","author":"MP DiGiovanna","year":"2005","unstructured":"DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;6:1152\u201360","journal-title":"J Clin Oncol"},{"key":"9419_CR32","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1158\/1078-0432.CCR-0951-3","volume":"10","author":"GE Konecny","year":"2004","unstructured":"Konecny GE, Meng Y, Untch M, et al. Association between HER-2\/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706\u201316","journal-title":"Clin Cancer Res"},{"key":"9419_CR33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2000.18.7.1423","volume":"18","author":"B Linderholm","year":"2000","unstructured":"Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000;18:1423\u201331","journal-title":"J Clin Oncol"},{"key":"9419_CR34","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.bjc.6600555","volume":"87","author":"P Manders","year":"2002","unstructured":"Manders P, Beex LV, Tjan-Heijnen VC, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002;87:772\u20138","journal-title":"Br J Cancer"},{"key":"9419_CR35","first-page":"109","volume":"4","author":"R Zeillinger","year":"1989","unstructured":"Zeillinger R, Kury F, Czerwenka K, et al. Her-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989;4:109\u201314","journal-title":"Oncogene"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/ASO.2006.03.032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/ASO.2006.03.032\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/ASO.2006.03.032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:20:44Z","timestamp":1572952844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/ASO.2006.03.032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,16]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["9419"],"URL":"https:\/\/doi.org\/10.1245\/aso.2006.03.032","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,16]]}}}